Purpose of this Study
If you join this study, you will receive a medicine called ASP546C through a vein every three weeks. You will also give blood and urine samples so doctors can check your health and how your body responds to the treatment. During the study, you will have regular scans such as CT or MRI to see how your cancer is changing.
Who Can Participate?
Eligibility
People can join this study if they are adults who have cancer that has spread or grown and cannot be cured with surgery. The cancer must have a special marker called CLDN 18.2. They must have already tried at least one treatment before. The study includes several types of cancer, such as cancers of the stomach and food tube, pancreas, bile ducts, colon, lungs, ovaries, and breast.
Age Range
18-110
Looking for Healthy Participants
No
What is Involved?
Description
The purpose of this study is to see if a new medicine called ASP546C is safe and works well for certain cancers. These cancers have a special marker called CLDN18.2. Researchers want to learn if the medicine can help treat these cancers and improve patient health.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
[546C-CL-0201] A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants with CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
Principal Investigator
John
Strickler
Protocol Number
PRO00119707
NCT ID
NCT07488676
Phase
I/II
Enrollment Status
Open to Enrollment